Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 4

Blood Cancer Journal

Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear. We examined the efficacy of different prophylactic regimens in 585 patients with newly diagnosed DLBCL and high-risk for CNS relapse, treated with rituximab, cyclophosphamide, doxorubicin, vincristine,...

  • A retrospective review of DLBCL patients treated at MSKCC w/HD MTX ppx failed to show a persistent benefit in decreasing CNS relapse rates. This study adds to the recent data questioning the utility of CNS prophylaxis.